Pharmacokinetic evaluation of single daily dose amikacin
- PMID: 1856147
- DOI: 10.1093/jac/27.suppl_c.63
Pharmacokinetic evaluation of single daily dose amikacin
Abstract
The pharmacokinetic parameters of amikacin given once daily were compared to those of amikacin given bd at different daily dosages. In adult patients, 'peak' serum concentrations (30 min after 30 min infusion) were linearly proportional to the dose given with the following equation:-'peak' = 4.23 (dose in mg/kg)-3.93 (r, 0.827; P less than 0.0001). Areas under curves were also proportional to the dose and were not affected by the schedule of administration (od or bd). Serum half-life was neither affected by the dose nor the schedule of administration. However, the half-life was approximately 3 h in adult patients with infections and was greater than 4 h in elderly patients. In multiple dose studies, no accumulation was observed either in children or adults. However, 'peak' serum concentrations increased slightly. New recommendations for therapeutic drug monitoring need to be formulated.
Similar articles
-
[Clinical, pharmacokinetic and therapeutic study of amikacin with single daily dose and in combination in neutropenic children with fever].Arch Pediatr. 1996 Sep;3(9):854-60. doi: 10.1016/0929-693x(96)87572-5. Arch Pediatr. 1996. PMID: 8949344 French.
-
Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections.J Antimicrob Chemother. 1991 May;27 Suppl C:73-9. doi: 10.1093/jac/27.suppl_c.73. J Antimicrob Chemother. 1991. PMID: 1906864 Clinical Trial.
-
Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients.J Antimicrob Chemother. 1997 Mar;39(3):431-3. doi: 10.1093/jac/39.3.431. J Antimicrob Chemother. 1997. PMID: 9096197
-
Amikacin once daily: a new dosing regimen based on drug pharmacokinetics.Scand J Infect Dis. 1990;22(5):575-9. doi: 10.3109/00365549009027099. Scand J Infect Dis. 1990. PMID: 2259867 Clinical Trial.
-
The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens.J Antimicrob Chemother. 1991 May;27 Suppl C:81-9. doi: 10.1093/jac/27.suppl_c.81. J Antimicrob Chemother. 1991. PMID: 1856148 Clinical Trial.
Cited by
-
Once daily antibiotic regimen in paediatric oncology.Arch Dis Child. 1994 Jun;70(6):484-7. doi: 10.1136/adc.70.6.484. Arch Dis Child. 1994. PMID: 8048816 Free PMC article. Clinical Trial.
-
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00425-19. doi: 10.1128/AAC.00425-19. Print 2019 Jul. Antimicrob Agents Chemother. 2019. PMID: 30988147 Free PMC article.
-
Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models.Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0139423. doi: 10.1128/aac.01394-23. Epub 2024 Jan 30. Antimicrob Agents Chemother. 2024. PMID: 38289076 Free PMC article.
-
Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.Antimicrob Agents Chemother. 1997 May;41(5):1115-9. doi: 10.1128/AAC.41.5.1115. Antimicrob Agents Chemother. 1997. PMID: 9145878 Free PMC article. Clinical Trial.
-
Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.Arch Dis Child. 1998 Jun;78(6):536-9. doi: 10.1136/adc.78.6.536. Arch Dis Child. 1998. PMID: 9713009 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical